[FETV=김창수 기자] Medytox announced that Daewoong Pharmaceutical (Daewoong)’s ’21-month import and sale ban’ order in the United States for the botulinum toxin formulation’Nabota’ (export name bulletin) will take effect on the 15th (U.S. local time).
This is the result of the rejection of President Biden and former President Trump of Daewoong and US partner Ebolus’ claims to reject the final decision of the International Trade Commission (ITC).
The ban on imports of Daewoong Nabota, developed by stealing Medytox’s trade secrets, from the US imports and the sale of Nabota stocks held by Ebolus was confirmed from the time the order went into effect. The deposit system, which was allowed to import or sell Nabota during the US presidential review period, is no longer allowed, and the deposits paid will also be passed on to the plaintiffs (Meditox and Allergan).
The order is based on ITC’s final decision on December 16 last year, which Nabota ruled as violating Article 337 of the Customs Act. With the participation of Daewoong and Ebolus, Medytox and Allergan, and ITC attorneys (Staff Attorney), ITC conducted a hearing for extensive evidence disclosure procedures, expert verification including full genome sequencing, and evidence hearing.
The ITC investigation proved that Daewoong developed Nabota by stealing Medytox’s botulinum strain and manufacturing process, and Daewoong’s claim that he found a botulinum strain in Yongin’s soil was clearly false. It was also proven that Ebolus developed and imported Nabota with Daewoong.
A Meditox official said, “As the US President accepted the ITC’s final judgment, it was revealed to be the obvious truth that Daewoong had stolen Medytox strains and manufacturing technology.” “Daewoong is not only legally responsible, but also to regulatory authorities and customers in various countries for a long time. “We also have to take moral responsibility for making false claims.”
Medytox predicted that Daewoong and Ebolus would also appeal against the ITC ruling and seek ways to prevent the import ban order from taking effect. However, since the arguments that Daewoong expected to raise were already dismissed by the ITC’s Unfair Investigation Bureau and the entire ITC committee of administrative judges, he was confident that even if Daewoong and Ebolus reused the same arguments repeatedly, the Federal Circuit Court would reject them all. have.
A Medytox official said, “Even if Daewoong appeals to the US Federal Circuit Court of Appeals, there is little possibility that the charges convicted of Daewoong will change through extensive evidence.” “Since the evidence convicted of Daewoong by ITC was submitted to Korean courts And the speed of the prosecution’s investigation will be rapid,” he added.